Literature DB >> 30059240

A Randomized Trial of Virtual Reality-Based Cue Exposure Second-Level Therapy and Cognitive Behavior Second-Level Therapy for Bulimia Nervosa and Binge-Eating Disorder: Outcome at Six-Month Followup.

Marta Ferrer-Garcia1, Joana Pla-Sanjuanelo1, Antonios Dakanalis2,3, Ferran Vilalta-Abella1, Giuseppe Riva3,4,5,6,7,8,9,10, Fernando Fernandez-Aranda6, Laura Forcano6, Nadine Riesco6, Isabel Sánchez6, Massimo Clerici4, Joan Ribas-Sabaté5, Alexis Andreu-Gracia5, Neli Escandón-Nagel9, Osane Gomez-Tricio7, Virginia Tena8, José Gutiérrez-Maldonado1.   

Abstract

This article reviews the 6-month followup data of a randomized, multicenter, parallel-group study conducted at five clinical sites in three European cities, which compared two second-level treatments for bulimia nervosa (BN) and binge eating disorder (BED): virtual reality-based cue exposure therapy (VR-CET) versus additional cognitive behavioral therapy (A-CBT). Post-treatment outcomes of this study were previously published and details of its design can be found at clinicaltrials.gov (identifier: NCT02237300). This article focuses on the evolution of symptoms assessed after 6 months of followup in a subgroup of 58 patients from the original study. In this study 64 patients with eating disorders (EDs) (35 with BN and 29 with BED), who still showed active episodes of binge eating by the end of a structured CBT program (first-level treatment), were randomly assigned to one of two second-level treatments (A-CBT or VR-CET). Frequency of binge and purge episodes, and attitudinal features of binge-related EDs (bulimia, drive for thinness, and body dissatisfaction) were assessed before starting the second-level treatment (n = 64), at the end (n = 64), and at 6-month followup (n = 58). Mixed between-within subject analyses of variance were used to compare outcomes of both second-level treatments over time. Although both treatment conditions showed statistically significant improvements at the end and after 6-month followup, obtained reductions were greater after VR-CET, regarding binge and purge episodes, as well as the decrease of self-reported tendency to engage in overeating episodes. Accordingly, abstinence from binge episodes were higher in VR-CET than A-CBT at followup (70 percent vs. 26 percent, respectively; χ2 = 11.711, p = 0.001). These results provide further support for the use of VR-CET as an effective second-level intervention for BN and BED treatment-resistant patients.

Entities:  

Keywords:  binge eating disorder; bulimia nervosa; cue exposure; followup; treatment; virtual reality

Mesh:

Year:  2018        PMID: 30059240     DOI: 10.1089/cyber.2017.0675

Source DB:  PubMed          Journal:  Cyberpsychol Behav Soc Netw        ISSN: 2152-2715


  5 in total

1.  Advancing science and practice using immersive virtual reality: what behavioral medicine has to offer.

Authors:  Susan Persky; Megan A Lewis
Journal:  Transl Behav Med       Date:  2019-11-25       Impact factor: 3.046

2.  Bringing Virtual Reality From Clinical Trials to Clinical Practice for the Treatment of Eating Disorders: An Example Using Virtual Reality Cue Exposure Therapy.

Authors:  Theresa Brown; Emily Nauman Vogel; Debra L Safer; Cristin D Runfola; Sarah Adler; Cara Bohon; Kim Bullock; Katherine Nameth; Giuseppe Riva
Journal:  J Med Internet Res       Date:  2020-04-23       Impact factor: 5.428

3.  Virtual Reality and Psychedelics for the Treatment of Psychiatric Disease: A Systematic Literature Review.

Authors:  Federico J Gómez-Busto; Mario I Ortiz
Journal:  Clin Neuropsychiatry       Date:  2020-12

4.  A tranquil virtual reality experience to reduce subjective stress among COVID-19 frontline healthcare workers.

Authors:  Elizabeth Beverly; Laurie Hommema; Kara Coates; Gary Duncan; Brad Gable; Thomas Gutman; Matthew Love; Carrie Love; Michelle Pershing; Nancy Stevens
Journal:  PLoS One       Date:  2022-02-09       Impact factor: 3.240

Review 5.  Various Types of Virtual Reality-Based Therapy for Eating Disorders: A Systematic Review.

Authors:  Julia Ciążyńska; Janusz Maciaszek
Journal:  J Clin Med       Date:  2022-08-24       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.